279 related articles for article (PubMed ID: 14732596)
1. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
Heresco-Levy U; Ermilov M; Lichtenberg P; Bar G; Javitt DC
Biol Psychiatry; 2004 Jan; 55(2):165-71. PubMed ID: 14732596
[TBL] [Abstract][Full Text] [Related]
2. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Heresco-Levy U; Javitt DC; Ebstein R; Vass A; Lichtenberg P; Bar G; Catinari S; Ermilov M
Biol Psychiatry; 2005 Mar; 57(6):577-85. PubMed ID: 15780844
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Heresco-Levy U; Javitt DC; Ermilov M; Mordel C; Silipo G; Lichtenstein M
Arch Gen Psychiatry; 1999 Jan; 56(1):29-36. PubMed ID: 9892253
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Heresco-Levy U; Ermilov M; Shimoni J; Shapira B; Silipo G; Javitt DC
Am J Psychiatry; 2002 Mar; 159(3):480-2. PubMed ID: 11870017
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
6. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
[TBL] [Abstract][Full Text] [Related]
7. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
8. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
9. Risperidone versus other atypical antipsychotic medication for schizophrenia.
Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
11. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
David SR; Taylor CC; Kinon BJ; Breier A
Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
[TBL] [Abstract][Full Text] [Related]
12. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Cuesta MJ; Peralta V; Zarzuela A
Schizophr Res; 2001 Mar; 48(1):17-28. PubMed ID: 11278151
[TBL] [Abstract][Full Text] [Related]
13. Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.
Kores Plesnicar B; Zalar B; Tomori M; Krajnc I
Wien Klin Wochenschr; 2003 Jan; 115(1-2):58-62. PubMed ID: 12658913
[TBL] [Abstract][Full Text] [Related]
14. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
[TBL] [Abstract][Full Text] [Related]
16. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
Kim KS; Pae CU; Chae JH; Bahk WM; Jun TY; Kim DJ; Dickson RA
J Clin Psychiatry; 2002 May; 63(5):408-13. PubMed ID: 12019665
[TBL] [Abstract][Full Text] [Related]
17. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
18. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Tran PV; Hamilton SH; Kuntz AJ; Potvin JH; Andersen SW; Beasley C; Tollefson GD
J Clin Psychopharmacol; 1997 Oct; 17(5):407-18. PubMed ID: 9315992
[TBL] [Abstract][Full Text] [Related]
19. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Casey DE; Daniel DG; Wassef AA; Tracy KA; Wozniak P; Sommerville KW
Neuropsychopharmacology; 2003 Jan; 28(1):182-92. PubMed ID: 12496955
[TBL] [Abstract][Full Text] [Related]
20. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
Tollefson GD; Andersen SW; Tran PV
Biol Psychiatry; 1999 Aug; 46(3):365-73. PubMed ID: 10435202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
